28 Feb
0
This post was originally published on this site
Bristol-Myers Squibb Co.’s $US74 billion takeover of Celgene is in jeopardy after Bristol-Myers’ second-largest shareholder turned against it. Wellington Management, which owns a 7.7% stake in Bristol-Myers, laid out three reasons it opposed the deal.
More »